2Kolodziejczyk B, Duleba AJ, Spaczynski RZ, et al. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril, 2000, 73(6): 1149-1154.
3Velazquez BM, Mendoza S, Hame T, et al. Metformin the rapythepolycystic ovary syndrome reduces hyperinsulinemia, insulinResistance, hyperandrogenemia and systolic blood pressure. While facilitating normal menses and Pregnancy. Metabolism, 1994, 43 (5): 647-654.
4Dale PD, Tanbo T, Haug E, et al. The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome. Hum Reprod, 1998, 13 (3): 567-570.
5Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome[J].Hum Reprod,2001,16(1):36-42.
6Fruzzetti F, Berris C, Parrini D. Treatment of Hirsutism comparisons between different antiandrogens with central and peripheral effects [J]. Fertil Steril, 1999,71(3):445 - 451.
7Ibanez L, Dezegher F. Low dose combination of flutamide,metformin and an oral contraceptive for non obese, young women with polycystic ovary syndrome[J]. Hum Reprod,2003,18(1) :57- 60.
8Morin P L, Vauhkonen I, Koivunen R, et al. Endocrine and metabolic effects of metformin versus ethinyl estradiol -cyproterone acetate in obese women with polycystic ovary syndrome:a randomezed study [J].The Journal of Clinical Endocrinology & Metablism,2000,85(9):3161 - 3168.
9Morin P L, Vauhkonen I, Koivunen R, et al. Metformin versus ethinyl estradiol - cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome:a randomized study[J].The Journal of Clinical Endocrinology & Metabolism,2003,88(1):148 - 156.
10Tartagn M, Schonauer L M, Salvia M A D, et al. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism[J]. Fertility Sterility,2000,73(4):718 - 723.
2JING Z, LIANG ZX, TAI XW, et al. The effects of Diane-35 andm etform in intreatment of polycystic ovary syndrom e: an updated system at iereview[J].Gynecol Endocrinol, 2008,24: 590-600.
3WU Jie, ZHU Yiqing, JIANG Yunfei, et al. Effects of metfonnin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome [ J]. Gynecological Endocrinology, 2008,24(7): 592-398.
4Manneras-holm L, Leonhardt H, Kullberg J, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance [ J ]. The Journal of Clinical Endocrinology and Metabolism, 2011,96 (2) : 304-311.
5Ketel 1 J,Stehouwer C D,Henry R M,et al. Greater arterial stiff- ness in polycystic ovary syndrome (PCOS) is an obesity-but not a PCOS-associated phenomenon[J]. The Journal of Clinical En- docrinology and Metabolism, 2010,95(10) : 4566-4575.
6Pasquali R, Gambineri A, Cavazza C, et al. Heterogeneity in the responsiveness to long-term lifestyle intervention and predictabili- ty in obese women with polyeystic ovary syndrome[J]. European Federation of Endocrine Societies, 2011,164( 1 ) : 53-60.
